Coronary Artery Disease Therapeutics expected to increase at significant growth rate through 2022
The incidence of chronic diseases such as diabetes, obesity, and high blood pressure is increasing across the globe. This creates a huge economic burden on the global healthcare system. Independent research on the coronary artery disease therapeutics market has identified that the increase in number of chronic diseases will be one of the major factors that will have a positive impact on market growth during the next few years.
A large number of patients are experiencing a low quality of life due to the uncontrolled blood sugar level. This can result in death. According to studies, countries such as the US have the largest number of diabetic patients. This will further boost the demand for coronary artery disease therapeutics.
The rise in number of mergers and acquisitions, product extensions, and the rising investments in R&D activities will strengthen the market’s competitive environment. The consumption of, and demand for cardiovascular disease (CAD) drugs is increasing due to the rising incidences of heart disease in the region.
The region is also heavily investing in the healthcare sector, which in turn, will drive the coronary artery disease therapeutics market’s growth and impact in the region. The US is the major revenue generator in the region due to the presence of the pharmaceutical giants and high prevalence rate of CAD.